Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

globenewswire

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension – NEWSnet – News… as it used to be

More Press Releases

June 23, 2026

X-tosis Receives Grant from The Michael J. Fox Foundation to Advance Novel Parkinson’s Disease Therapy

June 23, 2026

iSpring Announces Amazon Prime Day 2026 Savings of Up to 40% on Premium Water Filtration Solutions

June 23, 2026

HelixIntel Expands HelixCMMS with Fleet Management, Bringing Vehicles, Drivers, and Maintenance Into One Platform

June 23, 2026

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

X-tosis Receives Grant from The Michael J. Fox Foundation to Advance Novel Parkinson’s Disease Therapy

iSpring Announces Amazon Prime Day 2026 Savings of Up to 40% on Premium Water Filtration Solutions

HelixIntel Expands HelixCMMS with Fleet Management, Bringing Vehicles, Drivers, and Maintenance Into One Platform

Hallmark Venture Group, Inc. Completes Transformation into Drone Technology Company, Plans Corporate Name Change to SDR Drone, Inc.